Increased expression of pro-angiogenic factors such as VEGF and bFGF can lead to enhanced tumor vascularization, thereby reducing the efficacy of sorafenib’s anti-angiogenic effects [143,144]. The gene discussed is VEGFA; the disease is neoplasm.